Combined fertility treatment available

Merck Serono has launched Pergoveris (follitropin alfa/lutropin alfa), indicated for the stimulation of follicular development in women with severe lutinising hormone (LH) and follicle stimulating hormone (FSH) deficiency.

Treatment with Pergoveris should be initiated under the supervision of a physician experienced in the treatment of fertility problems and given as a course of daily injections.


Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response. A recommended regimen commences with one vial of Pergoveris daily.

Further information: Merck Serono 020 8818 7200

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more